THE PLATFORM

Proprietary mRNA + LNP Platform with AI-Driven Antigen Design

Pinion's core platform integrates three innovations: AI-optimized antigen selection, engineered LNP delivery, and a dual-arm immune activation strategy, to produce immunotherapeutics with efficacy profiles not achievable with conventional approaches.

AI-Driven Discovery

Proprietary antigen selection optimized for MHC binding, T cell induction, and neutralizing antibody response.

mRNA + LNP Delivery

Engineered LNP for enhanced lymph node trafficking, APC uptake, and superior MHC-I loading vs. protein vaccines.

Dual Immune Activation

Simultaneous induction of CD8⁺ cytotoxic T lymphocytes and virus-neutralizing antibodies for maximum efficacy.

Derisked by Prior Data

Each program supported by prior Phase 1–3 clinical evidence informing antigen selection and proof-of-concept.

Next Generation Formulation

Pinion’s proprietary LNP is engineered for enhanced delivery, APC uptake, and immune responses.

Jeon JH et al. Int J Nanomedicine. 2025;20:9389-9405. doi:10.2147/IJN.S527822

AI-Designed Prefusion-like gB

Enhances HSV-1, HSV-2, EBV-Neutralizing Antibody Responses

DC Antigen Reprogramming Technology

Creates Potent CD8+ T cell Activation by Enhancing MHC-I-Peptide Binding and Elimination of Self-Antigen Competition